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Nanoparticle (NP) research has emerged as one of the top scientific fields due to the
unique properties of nanomaterials with tremendous potential use in medicine and other
fields.1,2 In contrast to traditionally used bulk materials, NPs possess unique biochemical, electronic, magnetic, and optical properties that rely on their sub-micrometer size
(,1 µm) and their high surface-to-volume ratio.3 Nanoscale materials have now entered
clinical trials with more than 100 agents being evaluated or approved by the US Food
and Drug Administration.4 The current clinical nanomedicine approaches investigate
many different diseases (ClinicalTrials.gov) but mainly focus on the imaging and treatment of cancer.5,6 Compared to most traditional therapeutics, NP-based drug delivery
systems (DDSs) facilitate the fine-tuning of many important properties influencing the
drug pharmacokinetics including solubility, circulation time, and target-specific distribution.7 Although current commercial nanodrugs are still single functional, NPs can be
engineered as multifunctional systems allowing several functions at the same time, eg,
specific targeting, controlled drug release, and in vivo imaging.8 However, integrating
several nanomaterials into one multifunctional system remains challenging and is the
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Introduction: Siliceous nanoparticles (NPs) have been extensively studied in nanomedicine
due to their high biocompatibility and immense biomedical potential. Although numerous technologies have been developed, the synthesis of siliceous NPs for biomedical applications mainly
relies on a few core technologies predominantly intended to produce spherical-shaped NPs.
Methods: In this context, the impact of different morphologies of siliceous NPs on biodistribution in vivo is limited. In the present study, we developed a novel technique based on an aerosol
silane reactor to produce sintered silicon NPs of similar size but different surface areas due
to distinct spherical subunits. Silica-converted particles were functionalized for radiolabeling
with copper-64 (64Cu) to systematically analyze their behavior in the passive targeting of A431
tumor xenografts in mice after intravenous injection.
Results: While low nonspecific uptake was observed in most organs, the majority of particles
were accumulated in the liver, spleen, and lung. Depending on the morphologies and functionalization, significant differences in the uptake profiles of the particles were observed. In terms
of tumor uptake, spherical shapes with lower surface areas showed the highest accumulation
and tumor-to-blood ratios of all investigated particles.
Conclusion: This study highlights the importance of shape and fuctionalization of siliceous
NPs on organ and tumor accumulation as significant factors for biomedical applications.
Keywords: silicon, silica, human tumor xenograft, PEGylation, 64Cu
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subject of intensive research.9 Nevertheless, much preclinical
research is focused on the development of multifunctional
agents to merge therapeutic and diagnostic modalities in one
single compound and thus bring us closer to the long-conceived
dream of “theranostics”.10,11
The immense interest in nanomedicine led to the development of numerous DDSs including micelles, liposomes, proteins, dendrimers, and polymers.12 Last but not least, inorganic
materials have been studied for their potential use in nanomedicine since they offer advantages in terms of synthesis and
stability.13 Most of the inorganic materials in nanomedicine
are either based on noble metals or based on metal oxides,
but concerns about the toxicity of some of these compounds
arose and are subject of intense discussion.14–17 A special class
of inorganic nanomaterials is based on semiconductor silicon
(Si) and its oxide silica (Si dioxide [SiO2]).18–21 Siliceous
materials have been studied as inorganic alternatives with low
toxicity for nanomedicine due to their high biocompatibility
and nontoxic degradation products, eg, nontoxic silicic acid
that is rapidly excreted by the kidneys.22
Nowadays, silica NPs (SiO2NPs) are the best-investigated
class of siliceous nanomaterial in biomedicine due to their high
biocompatibility, degradability, tunable morphology, and ease
of modification.20–23 Moreover, silica can be integrated with
other nanomaterials to achieve multifunctionality, eg, by coating other inorganic materials such as gold and iron oxide to produce core–shell NPs.24 As a most prominent example, Cornell
dots (C-dots) possess a fluorescent core and represent the first
SiO2NPs under clinical investigation.25,26 Biomedical SiO2NPs
are typically produced by various bottom-up approaches where
precursor particles grow in size via chemical reactions. Most of
the current approaches are based on sol–gel methods evolved
from the Stöber process introduced in 1968.27 This approach
allows the production of monodisperse silica particles in varying sizes (5–2,000 nm) by the hydrolysis and condensation of
silanes in aqueous solution and in the presence of a mineral
acid or base as catalyst. By adding surfactants to the process,
pores of different shapes and sizes can be integrated into the
silica network. This allows the generation of mesoporous
SiO2NPs with high surface areas that are promising platforms
for robust and controllable drug delivery.28 Recently, a new
class of silica hybrid analogs has emerged, using various
organosilica precursors during the sol–gel synthesis. These
(periodic) mesoporous organosilica NPs contain organic
bridges in their silica network that facilitates the functionalization for biomedical applications.21
The other class of siliceous nanomaterial being investigated in biomedicine is based on elemental Si.19 In general,
biomedical Si NPs (SiNPs) are characterized by a fast
7376

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

hydrolytic in vivo degradation and renal clearance.22 Porous
Si (pSi) NPs are fabricated in various top-down approaches
relying on etching and milling. Most frequently electrochemical etching of the surface of a Si wafer is used to produce both
spherical-shaped and irregularly shaped pSi.29,30 Recently, pSi
NPs have received attention as promising multifunctional platforms for drug delivery and noninvasive imaging due to high
drug loading capacity and adjustable pore sizes.19 Although
thin layers of native oxide are usually observed, pSi NPs are
often oxidized in controlled conditions to produce defined
layers of SiO2 of varying thicknesses to archive higher in
vivo stability, improved functionalization, and better drug
release.19,29 In terms of imaging, oxidized pSi NPs exhibit
intrinsic near-infrared photoluminescence due to quantum
confinement effects and defects at the Si–SiO2 interface,
which can be used for in vivo tracking.31 In contrast, this intrinsic luminescence of pSi NPs is rapidly lost under physiological
conditions and other imaging technologies such as MRI, PET,
and SPECT have successfully been implemented.24 In contrast
to pSi, nonporous SiNPs can be typically produced by numerous technologies including both top-down and bottom-up
approaches but also mixtures of both involving decomposition
and re-assembly of precursors.32 Currently, these approaches
are predominantly used to synthesize smaller (2–8 nm), colloidal quantum dots (QDs), which are highly attractive for in
vitro and in vivo imaging applications due to their low toxicity
compared to conventional heavy metal QDs.33
In this article, we implemented a novel aerosol reactorbased approach to produce various siliceous NPs for
potential biomedical applications. First, nonporous SiNPs
were synthesized by thermal decomposition of silane in an
aerosol reactor. By adjusting the reactor conditions, we could
control the synthesis process to produce three differently
shaped SiNPs of similar final size (~170 nm) but consisting
of differently sized smaller primary particles. Outer layers of
these SiNPs were converted by thermal oxidation into SiO2 to
obtain higher biostability in vivo. To analyze their biomedical potential, the functionalized NPs were radiolabelled with
copper-64 (64Cu) and injected in tumor-bearing mice. For
comparison, in vivo studies were done in parallel with spherical SiO2NP of similar size that was produced by a standard
sol–gel approach. Biodistribution of both polyethylene glycol
(PEG)ylated and non-PEGylated NPs was analyzed after 4
and 24 hours of circulation and tissue uptake discussed in
light of morphology and functionalization. Our data show the
value of these aerosol-synthesized Si–SiO2 nanocomposites
for potential biomedical applications and give insight into
the impact of morphology and functionalization of these NPs
on in vivo organ distribution.
International Journal of Nanomedicine 2018:13
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Materials and methods
Chemicals and reagents
All chemicals and reagents were purchased from commercial
suppliers and used without further purification. Silane in
helium (0.9% SiH4), helium, and nitrogen (all ultrahigh purity)
were obtained from Airgas (Radnor, PA, USA) and used for
synthesizing SiNPs in the gas phase. Ultrapure type I water
(resistivity: 18.2 MΩ⋅cm) was obtained from an in-house
PURELAB flex system from Evoqua Water Technologies
(Pittsburgh, PA, USA). (3-Aminopropyl)-triethoxysilane
(APTES, 99%), ammonium acetate (NH4OAc) ($99.99%
trace metal basis), Chelex 100 sodium form, and dimethyl
sulfoxide (DMSO, anhydrous, $99.9%) were purchased
from Sigma-Aldrich Co. (St Louis, MO, USA). Absolute
ethanol (200 proof) was bought from Decon Labs (King of
Prussia, PA, USA), and ITLC-SG paper was bought from
Agilent Technologies (Santa Clara, CA, USA). Chelator
2-S-(4-isothiocyanatobenzyl)–1,4,7-triazacyclononane1,4,7-triacetic acid (p-SCN-Bn-NOTA, $94%) was purchased
from Macrocyclics (Plano, TX, USA), cross-linker MALPEG-SCM (molecular weight: 5 kDa) was purchased from
Creative PEGWorks (Chapel Hill, NC, USA), and diethylenetriaminepentaacetic acid (DTPA, 98.5%) was purchased
from Strem Chemicals (Newburyport, MA, USA). 64Cu
(t1/2=12.7 hours, β+=17%, β-=39%, electron capture =43%,
Emax =0.656 MeV) was produced by a (p,n) reaction on enriched
64
Ni on a TR-19 biomedical cyclotron (Advanced Cyclotron
Systems Inc., Richmond, BC, Canada) at Mallinckrodt Institute of Radiology, Washington University School of Medicine (WUSM) and purified with an automated system using
standard procedures.34,35 For radiolabeling, a stock solution of
64
CuCl2 was diluted with a 10-fold excess of 0.1 M NH4OAc
(pH 5.5). FBS, DMEM, PBS (1×), and trypsin-EDTA were
obtained from Thermo Fisher Scientific (Waltham, MA, USA).
Sterile, nonpyrogenic saline (0.9% sodium chloride injection)
was purchased from Hospira (Lake Forest, IL, USA).

Synthesis of aerosol-synthesized NPs
Nonspherical siliceous NPs (NP1, NP2, and NP3) were synthesized via silane pyrolysis in a silane furnace aerosol reactor.
The reactor was made of a stainless steel tube (1″ diameter and
18″ long) inside a Lindberg Furnace (Thermo Fisher Scientific). The reactor was fed by gas from three cylinders with a
fixed chemical composition of silane in helium (0.9% SiH4),
helium, and nitrogen. Mass flow controllers (MKS Instruments,
Andover, MA, USA) were used to independently regulate the
flow of each gas stream into the reactor. A pressure transducer
(WIKA Instruments, Klingenberg am Main, Germany) was
used to monitor pressure. Data acquisition and user interface
International Journal of Nanomedicine 2018:13
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were achieved via LabVIEW (National Instruments, Austin,
TX, USA) and a data acquisition board (National Instruments). NP1 was synthesized by feeding the reactor with
0.004% silane, 19.021% helium, and 80.975% nitrogen using
a reactor temperature of 1,000°C. Produced Si particles were
collected on quartz filters (Advantec MFS, Dublin, CA, USA)
for 10 hours during continuous reactor operation. NP2 and
NP3 were produced in a similar way using 0.02% silane and
99.98% helium under constant flow using temperatures for
the silane pyrolysis of 600°C (NP2) or 1,000°C (NP3) and
10 hours continuous reactor operation. Outer layers of SiNPs
were converted into silica by thermal oxidation using particlespecific conditions. NP1 was isothermally treated for 1 hour at
900°C by increasing the temperature with 1°C/min up to 400°C
and 5°C/min to the final temperature. NP2 was oxidized for
5 minutes at 500°C. NP3 was heated for 10 hours at 600°C,
followed by 10 hours at 900°C. Right before further experimentation, NPs were diluted in ultrapure water to 0.9 mg/mL
(ie, 15 mM) and well-dispersed by ultrasonic treatment.

Synthesis of spherical NPs
Spherical NP4 was synthesized using a sol–gel method
following the procedure outlined by Möller and Bein.36
To synthesize, 4 mL of absolute ethanol and 2 mL of ultrapure
water were combined in a 50 mL glass vial and sonicated for
3 minutes at room temperature (RT) using a bath sonicator.
While maintaining sonication, 200 µL of tetraethyl orthosilicate (TEOS) was pipetted to the solution and sonicated
for an additional 3 minutes. After the addition of 0.5 mL of
ammonium hydroxide (NH4OH), the solution was sonicated
for an additional 7–12 minutes and NP4 was separated by
centrifugation. The supernatant was discarded, and the vials
were kept at 60°C in an oven for 1 hour to get SiO2NPs in
powdered form. NP4 was treated and stored as described
earlier for aerosol-synthesized particles.

Surface modification of NPs with amines
The silica surface of the NPs was functionalized with amine
groups by treatment with APTES. Typically, 60 µmol of NPs
was centrifuged (16,800× g, 10 minutes) and resuspended
in 7.6 mL of 5% H2O diluted in absolute ethanol (pH 5.0).
For silanization, 400 µL of APTES was added to a final
concentration of 5%. The mixture was incubated for 3 days
at 60°C in sealed glass vials and vortexed from time to time.
Unreacted APTES was removed by washing three times with
70% ethanol. The final product was dispersed in ultrapure
water to 0.1 µmol/µL. The presence of primary amines was
determined by a Ninhydrin Test Kit (AnaSpec, Fremont, CA,
USA) according to the manufacturer’s recommendations.
submit your manuscript | www.dovepress.com
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NOTA and PEG conjugation to aminefunctionalized NPs
Stock solutions of the chelator p-SCN-Bn-NOTA (2 mM)
and cross-linker MAL-PEG-SCM (20 mM) were prepared by
diluting the compounds in DMSO and stored at -80°C until
use. Thirty micromoles of the APTES-treated NPs was distributed in acid-washed conical tubes (1.5 mL; Thermo Fisher
Scientific), centrifuged (16,800× g, 10 minutes), and washed
once with 1 mL of DMSO. NPs were dispersed in 1 mL/tube
DMSO, and p-SCN-Bn-NOTA stock solution was added to a
molar ratio of 1.2–1 (NP to p-SCN-Bn-NOTA). To prepare
PEGylated NPs, MAL-PEG-SCM stock solution was additionally added to a molar ratio of 1.2–1–10 (NP to SCN-BnNOTA to MAL-PEG-SCM). After adjusting the pH to 8.5,
the tubes were incubated in an Eppendorf ThermoMixer
(Hamburg, Germany) at 37°C for 1 hour shaking (1,000 rpm)
to prepare the final NOTA or NOTA/PEG-conjugated NPs.

Cu radiolabeling of NOTAfunctionalized NPs
64

To radiolabel with radioactive 64Cu, NOTA-conjugated NPs
(both non-PEGylated and PEGylated) were washed once
with 1 mL/tube of radiolabeling buffer (0.1 M NH4OAc,
pH 5.5). After centrifugation, NPs were resuspended in
200 µL/tube of radiolabeling buffer containing about 1 mCi
of 64Cu (37 MBq). Radiolabeling occurred during an 1 hour
incubation at 37°C and shaking at 800 rpm in an Eppendorf ThermoMixer. To complex unreacted 64Cu, pelleted
NPs were resuspended in 800 µL/tube PBS and 200 µL of
chelex-treated 50 mM DTPA solution (pH 7.0) and incubated
for further 5 minutes at 37°C (800 rpm). After washing
once with PBS, the final products from tubes containing
similarly treated preparations of NPs were combined in one
tube. Centrifuged NPs were re-dispersed in sterile saline to
obtain 10 µCi (0.37 MBq) per injection (100 µL/mouse).
The radiochemical purity of the final products after 64Curadiolabeling was analyzed by instant thin layer chromatography (ITLC). Silica gel-impregnated glass fibers were
spotted 2 cm from the bottom with 1 µL of final products.
The plates were developed in chelex-treated 50 mM DTPA
(pH 7.0) solution until the solvent reached 7 cm. The dried
plates were analyzed employing a BioScan radio-TLC Imaging Scanner AR-2000 (Eckert & Ziegler, Berlin, Germany)
using the WinScan software (Version 3.13).

Characterization of bare and
functionalized NPs
The NPs were characterized by different techniques including transmission electron microscopy (TEM), dynamic light
7378
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scattering (DLS), laser Doppler velocimetry (LDV), and
NP tracking analysis (NTA). TEM images were obtained
using an FEI Tecnai G2 Spirit instrument (Thermo Fisher
Scientific). To prepare TEM samples, 10 µL of each NP
sample was pipetted on parafilm. Carbon-coated copper
grids (200 mesh; TED Pella, Redding, CA, USA) were
placed with the carbon site onto the drops and incubated
for 1 minute. Excess samples were carefully removed with
the outer tip of Whatman filter papers (GE Healthcare,
Chicago, IL, USA) and grids air-dried prior to TEM imaging. A Malvern Zetasizer Nano ZS (ZEN3600; Malvern
Instruments, Malvern, UK) was used to measure particle
sizes by DLS employing disposable polystyrene cuvettes and
ultrapure water as diluent. To analyze the zeta potential (ZP)
by LDV, the water-dispersed NPs were filled in disposable
polystyrene cuvettes and measured in the Malvern Zetasizer
Nano ZS (ZEN3600) equipped with a universal dip cell.
Sizes of the bare particle were further determined by NTA
in a NanoSight NS300 instrument (Malvern Instruments)
after dilution in ultrapure water and illumination by a green
(532 nm) laser light.

Cell culture
The epidermoid carcinoma cell line A431 was purchased
from the American Type Culture Collection (ATCC)
(Manassas, VA, USA) and cultivated in complete growth
medium (DMEM supplemented with 10% of heat-inactivated
FBS) in low passage number in a humidified cell incubator
(5% CO 2, 37°C). For xenograft mouse models, A431
was expanded in T150 tissue culture flasks and harvested
by trypsinization when reaching 70%–90% confluency.
Harvested cells were washed three times with PBS and
diluted to 5×107/mL in PBS.

Biodistribution
Animal experiments were conducted in compliance with the
Guidelines for Care and Use of Research Animals established
by Washington University Animal Studies Committee using
a protocol approved by the committee. The 5–6-week-old
female athymic nude mice (Foxn1nu/Foxn1+) were purchased
from Envigo (Huntingdon, UK) and housed under pathogenfree conditions in the WUSM animal facility. Mice with
an average weight of 25 g were anesthetized by the inhalation of 1%–2% isoflurane in 100% oxygen and implanted
subcutaneously on the right shoulder with 5.0×106 A431
cells suspended in 100 µL of PBS. Tumors were allowed to
grow for 2 weeks reaching final tumor weights ~350 mg on
average. In vivo biodistribution studies were conducted in
the Washington University Small Animal Imaging Facility.
International Journal of Nanomedicine 2018:13
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Isoflurane-anesthetized, tumor-bearing mice were intravenously injected with about 10 µCi (0.37 MBq) of NP-NOTA64
Cu or NP-NOTA-PEG-64Cu via the tail vein. After each
time point (4 and 24 hours), mice were sacrificed by CO2
euthanasia and cervical dislocation. Tumors and selected
organs (blood, muscle, lung, liver, spleen, kidney, bladder,
heart, bone, pancreas, stomach, and intestine) were collected, weighted, and radioactively counted with a Beckman
Gamma-8000 counter (Beckman Coulter, Brea, CA, USA).
Tumor and organ uptake were analyzed and calculated as
percentage of injected dose per gram (%ID/g).

Statistics

Data are represented as the mean ± SD of at least three independent experiments. Multiple comparisons were conducted
by GraphPad Prism 7 (GraphPad Software, La Jolla, CA,
USA) implementing one-way ANOVA, followed by Tukey’s
multiple comparison test (****P,0.0001; ***P,0.001;
**P,0.01; *P,0.05; nsP$0.05).

Results
Synthesis of NPs
A novel aerosol reactor approach was developed for the
synthesis of siliceous NPs with varying morphologies.37 The
reactor setup (Figure S1A) and synthesis process can be
outlined as follows. A stream of 0.9% silane gas in helium is
further diluted with a carrier gas stream of either a helium/
nitrogen mixture (NP1) or helium (NP2 and NP3). The mixed
gas stream then flows continuously through a thermal reactor,
made of a stainless steel tube inside a Lindberg furnace. Inside
the reactor, as the stream flows into hotter zones, the gas heats
up to a critical temperature where silane starts to pyrolise and
to undergo nucleation and condensation thus forming monomeric primary particles of several nanometers in diameter.
Depending on reactor conditions and silane concentration,
primary particles continue to grow by agglomeration to form
larger reversible structures (agglomerates). If the residence
time and temperature in the reactor are high enough, the
agglomerates might coalesce to form solid irreversible NPs
(aggregates). In general, the aerosol reactor design enabled the
accurate control of several process parameters including temperature (error proportional–integral–derivative controller:
,±1°C), gas concentrations (error of mass flow controllers:
,±5% of set point), and operation time. By controlling these
parameters, specific and highly reproducible morphologies of
synthesized SiNPs were obtained. For instance, the change
in the reactor temperature from 600°C to 1,100°C resulted
in an increase in the primary particle sizes and an increase in
sphericity (Figure S1B). The geometric mean of the primary
International Journal of Nanomedicine 2018:13
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particle size distribution for each temperature could be reproduced even by different operators. For 700°C, the geometric
mean of the primary particle size distribution was measured
to be 10.3±0.87 nm (± standard error [SE]). At 1,000°C, the
geometric mean of the primary particle size distribution was
29.4±0.59 nm (± SE), while final aggregate sizes were almost
unchanged typically with an SE of ±0.6% for the geometric
mean of the aggregate size distribution. As a common rule,
higher silane concentration leads to a reproducible increase in
primary particle sizes within the investigated dynamic range
of the reactor (ie, 25 ppm to 0.9% SiH4).
In this study, the reactor conditions were adjusted to synthesize three types of NPs with different primary particle sizes as
summarized in Table S1. The size distributions of the produced
NPs were monitored in real time by a scanning mobility particle
sizer (SMPS) to guarantee reproducible size distributions independent of the chosen conditions and run as well as to obtain
fairly constant final aggregate sizes between all three types of
NPs (Figure S1C). Final products were collected on quartz
filters showing black (NP1 and NP2) to gray colors (NP3)
(Figure S1D). To convert the Si surface to SiO2, products were
treated by thermal oxidation using particle-specific conditions.
Successful oxidation of particles was confirmed by changing
colors of final products from black/gray (Si) to white (SiO2).
The conversion of Si into SiO2 is expected to have occurred
in a core–shell process, where the surface oxidizes first and
the core of the NP at the end.38 Conversion efficacy of Si into
SiO2 was calculated gravimetrically by weighing the filters
before and after the oxidation process reaching .90% (NP2)
or even .95% (NP1 and NP3). Control SiO2NPs of entirely
spherical shape were produced by a standard sol–gel method
as outlined in the “Materials and methods” section.

Characterization of bare NPs
The morphology of final NPs was first characterized by
TEM. The analysis of TEM pictures revealed nonspherical
shapes for all aerosol reactor-produced NPs (NP1, NP2,
and NP3). As a common characteristic, the NPs were built
from smaller primary particles of fairly spherical shape
and different sizes depending on the conditions used during the synthesis. In contrast, the sol–gel-produced control
particles (NP4) possessed uniform spherical shape. Figure 1
outlines the typical morphologies of the investigated NPs
based on their appearance in TEM using the following color
coding throughout this publication: NP1 in green, NP2 in
blue, NP3 in red, and NP4 in orange. To determine the size
of the final products, DLS analysis of water-dispersed NPs
was performed showing comparable final particle sizes
145±33 nm (NP1: 106±17 nm, NP2: 140±11 nm, NP3:
submit your manuscript | www.dovepress.com
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Figure 1 Overview about differently shaped siliceous NPs.
Notes: Representative TEM pictures (top) and the corresponding schematic sketch (bottom) of the NPs used within the study. The NPs are ordered according to their
relative surface area from the left (NP1: highest surface area) to the right (NP4: lowest surface area). The color marking (NP1: green, NP2: blue, NP3: red, NP4: orange) is
kept throughout the publication.
Abbreviations: NP, nanoparticle; TEM, transmission electron microscopy.

146±6 nm, and NP4: 187±5 nm) (Table 1). A low polydispersity index (PDI) was seen for NP3 (0.10±0.01) and NP4
(0.05±0.02), indicating narrow monodisperse distributions
of NPs. In contrast, higher PDIs were observed for the other

NPs suggesting moderate polydisperse distributions (NP1:
0.49±0.05; NP2: 0.34±0.04). NPs were additionally visualized by high-resolution NTA to confirm the particle sizes
obtained by DLS. The NTA data revealed slightly larger

Table 1 NP characterization by DLS
Sample

Size ± SD
(nm)

PDI ± SD
(nm)

Distribution

Zeta potential ± SD
(mV)

Stability

NP1
NP1-NH2
NP1-NOTA
NP1-NOTA-PEG
NP2
NP2-NH2
NP2-NOTA
NP2-NOTA-PEG
NP3
NP3-NH2
NP3-NOTA
NP3-NOTA-PEG
NP4
NP4-NH2
NP4-NOTA
NP4-NOTA-PEG

106±17
400±378
311±121
395±356
140±11
339±33
399±56
1,079±573
146±6
427±74
426±33
801±452
187±5
396±75
448±213
244±74

0.49±0.05
0.61±0.30
0.61±0.19
0.64±0.25
0.34±0.04
0.48±0.04
0.38±0.05
0.36±0.23
0.10±0.01
0.18±0.01
0.24±0.01
0.41±0.11
0.05±0.02
0.57±0.28
0.55±0.21
0.86±0.25

††
†††
†††
†††
††
††
††
††
†
††
††
††
†
†††
†††
†††

-30.3±3.8
14.1±0.9
9.3±1.5
0.6±0.8
-21.4±0.1
18.7±0.6
9.5±0.4
5.4±0.1
-25.6±1.1
20.5±0.4
10.3±0.4
-12.3±3.7
-40.9±0.4
4.9±0.3
-13.4±1.6
-2.4±0.3

‡‡‡‡
‡‡
‡
‡
‡‡‡
‡‡
‡
‡
‡‡‡
‡‡‡
‡‡
‡‡
‡‡‡‡
‡
‡‡
‡

Notes: Types of distribution in DLS measurements were defined as follows: † 0.0–0.1, narrow monodisperse; †† 0.1–0.5, moderate polydisperse; ††† .0.5, broad
polydisperse. The colloid stability in LDV analysis was defined as described below: ‡ ±0–10, highly unstable; ‡‡ ±10–20, relatively stable; ‡‡‡ ±20–30, moderately stable;
‡‡‡‡ .±30, highly stable. Averages were calculated from at least three (n=3) independent measurements. Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: DLS, dynamic light scattering; LDV, laser Doppler velocimetry; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PDI, polydispersity
index; PEG, polyethylene glycol.
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sizes of NPs with on average 174±18 nm. Sizes of NPs with
low PDI in DLS measurements were almost identical in
NTA (NP3: 148±77 nm; NP4: 188±46 nm). However, NPs
with higher PDIs in DLS showed increased particle sizes in
NTA, ie, NP1 (184±76 nm) and NP2 (175±65 nm). To gain
further information about the particle morphology, TEM pictures were analyzed by ImageJ (National Institute of Health,
Bethesda, MD, USA) to determine the average sizes of the
single spherical subunits. By measuring the spherical areas
(n=100), diameters of primary particles were calculated.
NP1 showed the smallest subunit sizes with only 6±2 nm in
diameter, followed by NP2 with 14±3 nm and finally NP3
with an average diameter of 41±11 nm (Figure S2). Due to
the monodisperse nature of the spherical control particles,
the ImageJ analysis was used to additionally confirm the
final particles sizes of NP4 with 187±39 nm. Based on
the appearance in TEM and the similar final particle sizes,
the relative surface areas of final particles were estimated
assuming a spherical composition of all final products. The
smallest surface area was anticipated for the entirely spherical
control particle NP4 and increased for the nonspherical NPs
depending on the sizes of their primary subunits from large
for NP3 (41 nm), via intermediate for NP2 (14 nm), to small
for NP1 (6 nm) (Figure 1).

Functionalization and characterization
of modified NPs
In preparation for 64Cu radiolabeling and in vivo tracking
in tumor-bearing mice, NPs were modified by various compounds, including APTES, NOTA, and PEG. First, bare NPs
were chemically treated with APTES to cover the surfaces
with organofunctional alkoxysilane molecules. Silanization
was performed for up to 72 hours at 60°C using 5% APTES
dissolved in an ethanol/water mixture. Successful functionalization of the various NPs was confirmed by a semiquantitative
ninhydrin test kit (data not shown). In the next step, the silanized
NPs were conjugated to the NOTA chelator using the aminereactive cross-linker p-SCN-Bn-NOTA. Primary amines of
silanized NPs were reacted with the isothiocyanate groups of
p-SCN-Bn-NOTA to form stable thiourea bonds in DMSO at
pH 8.5 for 1 hour at 37°C as described. To further investigate
the influence of PEGylation on biodistribution of the NPs,
amine-reactive MAL-PEG-SCM was optionally added during
the chelator reaction using a molar excess of MAL-PEG-SCM
to SCN-Bn-NOTA of 10–1. Primary amines of silanized NPs
reacted with the succinimidyl NHS ester group of MAL-PEGSCM to stable carboxamide bonds, thus adding an additional
5 kDa linear PEG chain to the functionalized NPs.
International Journal of Nanomedicine 2018:13
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The NPs were then characterized by DLS in order to
determine potential changes in particle sizes. The data for the
DLS measurements of water-dispersed NPs are summarized
in Table 1. On average, silanization of bare NPs by APTES
lead to about a threefold increase in particle size, independent
of the particle shape. NOTA conjugation to silanized NPs did
not change the size further. An approximate 1.7-fold increase
in particle size was observed when PEG was used. The PDI
for the DLS measurements was in the moderate polydisperse
range (0.1–0.5) for all functionalized samples of NP2 and
NP3. In contrast, broad polydispersity (.0.5) was observed
for NP1 and NP4 after all functionalization steps.
To investigate the influence of the surface modification
on stability, the ZPs of water-dispersed NPs were evaluated
(Table 1). As described below, the different functionalization
steps changed the ZPs of the NPs in similar ways independent of the particle type. In general, the bare particles gave
negative ZPs with an average of -30±8 mV, indicating
moderate (NP2 and NP3) to high (NP1 and NP4) stabilities.
Compared to these bare particles, surface modification by
APTES treatment increased (44±3 mV) the ZPs to 15±7 mV
suggesting reduced stabilities (relatively stable: NP1 and
NP2; moderately stable: NP3; and highly unstable: NP4).
The further addition of chelator NOTA to the silanized NPs
decreased (-11±6 mV) the ZPs to an average of 4±12 mV,
signaling even lower overall stabilities (relatively stable:
NP3 and NP4; highly unstable: NP1 and NP2). Similar to the
NOTA conjugation alone, the addition of both NOTA and
PEG to the silanized NPs resulted in a comparable decline
(-17±11 mV) of the ZPs close to zero (-2±8 mV), indicating again very low colloid stabilities (relatively stable: NP3;
highly unstable: NP1, NP2, and NP4).

Radiolabeling and biodistribution of NPs
As a final step, in vivo mouse studies were conducted in order
to determine the impact of the NP shape and PEGylation on
organ distribution and tumor uptake. Therefore, the various
types of NOTA-conjugated NPs were first radiolabeled with
64
Cu. To guarantee high radiochemical purity of the final
products before injection, ITLC of the 64Cu-radiolabeled
NPs was performed. The ITLC profiles confirmed the high
efficacy of radiolabeling with an average radiochemical
purity of 93%±12% as calculated from the regions of interests
(ROIs). For proper comparison, 10 µCi (0.37 MBq) of the
final radiolabeled NPs were injected in the tail vein in athymic nude mice bearing A431-tumor xenografts. Mice were
sacrificed after 4 or 24 hours to determine the uptake of the
radioactive NPs as %ID/g into selected organs and tumors.
submit your manuscript | www.dovepress.com
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The complete dataset of this biodistribution study is given in
Tables S2–S5, including all collected organs and the tumors.
Based on the distinct nature of the NPs, significant differences in the uptake profiles of the particles were observed.
In general, the highest uptake of radiolabeled NPs was seen
for lung, liver, spleen, kidneys, and intestine. In contrast,
tumors and all other investigated organs showed lower
overall uptake of radiolabeled NPs. To better emphasize
these differences, only the biodistribution data of relevant
organs and tumors are discussed separately and, in more
detail, below. The biodistribution of non-PEGylated NPs
in the major organs is shown in Figure 2A (4 hours) and
Figure 2B (24 hours), and that of PEGylated NPs is shown
in Figure 3A (4 hours) and Figure 3B (24 hours). Due to the
scale difference, the uptake in the tumors after 24 hours is
shown separately (Figure 4).

Lung uptake
The apparent uptakes of radiolabeled NPs into the
lungs showed dramatic differences between various
types of NPs. Very high initial lung uptake (non-PEG:
108.84±19.07%ID/g; PEG: 126.06±14.51%ID/g) was
observed for aerosol-synthesized NP1 possessing the highest
relative surface areas of all particles. In contrast to all other
types of NPs (all ,37.46%ID/g), the lung uptake of NP1 at

the 4 hours time point was significantly increased for both
non-PEGylated and PEGylated NPs (all P,0.0001). Interestingly, this high uptake of NP1 into the lungs was mostly
dependent on the circulation time but not on the PEGylation
status. The uptake in lungs clearly decreased after 24 hours
(non-PEG: 12.86±3.37%ID/g; PEG: 20.23±5.72%ID/g),
showing less significant differences compared to the other
NPs. Moreover, the calculated P-values of the non-PEGylated and PEGylated products confirmed that the lung uptake
of NP1 was independent of PEGylation (4 hours: P=0.2484;
24 hours: P=0.4278). According to this, PEGylation had no
significant effect on lung uptakes for the other NPs (4 hours:
all P.0.1128; 24 hours: all P.0.9999).
In summary, aerosol-synthesized NP1 with the highest
surface area of all particles showed superior lung uptake after
4 hours. This effect was almost negated after 24 hours when
compared with the other NPs. PEGylation had no significant
influence on lung uptake for any particle type.

Liver uptake
By analyzing the liver distributions, very significant differences were calculated for the aerosol-synthesized NP2
after PEGylation compared to all other NPs (all P,0.0007).
NP2 showed the highest liver uptake after PEGylation of
all NPs that was independent of the analyzed time point
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Figure 2 Biodistribution of NP-NOTA-64Cu in tumor-xenografted mice.
Notes: Athymic nude mice bearing A431 tumors were injected intravenously with 10 µCi of single conjugate. Mice were sacrificed after 4 hours (A) or 24 hours (B). Tumors
and selected organs were harvested, weighted, and analyzed by γ-counting to determine %ID/g. Data are expressed as mean ± SD %ID/g based on n=4 animals per group.
Statistical analysis was performed by one-way ANOVA, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01; *P,0.05). Green: NP1-NOTA64
Cu, blue: NP2-NOTA-64Cu, red: NP3-NOTA-64Cu, and orange: NP4-NOTA-64Cu.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.
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Figure 3 Biodistribution of PEGylated NP-NOTA-64Cu in tumor-xenografted mice.
Notes: Athymic nude mice bearing A431 tumors were injected intravenously with 10 µCi of single conjugate. Mice were scarified after 4 hours (A) or 24 hours (B). Tumors
and selected organs were harvested, weighted, and analyzed by γ-counting to determine %ID/g. Data are expressed as mean ± SD %ID/g based on n=4 animals per group.
Statistical analysis was performed by one-way ANOVA, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01; *P,0.05). Green: NP1-NOTAPEG-64Cu, blue: NP2-NOTA-PEG-64Cu, red: NP3-NOTA-PEG-64Cu, orange: NP4-NOTA-PEG-64Cu.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PEG, polyethylene
glycol.

(4 hours: 64.54±4.07%ID/g; 24 hours: 55.77±8.33%ID/g).
Furthermore, the high liver uptake of NP2 was unaffected by
PEGylation (4 hours: P=0.8864; 24 hours: P=0.9943), reaching similar high overall uptakes for the non-PEGylated NP2
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Figure 4 Tumor uptake of radiolabeled NPs in tumor-xenografted mice.
Notes: Tumor uptake was calculated based on the biodistribution data for nonPEGylated (left) and PEGylated (right) NP-NOTA-64Cu after 24 hours of circulation.
Data are expressed as mean ± SD %ID/g based on n=4 animals per group. Statistical
analysis was performed by one-way ANOVA, followed by Tukey’s multiple
comparison test (****P,0.0001; **P,0.01; *P,0.05). Green: NP1, blue: NP2, red:
NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram;
NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PEG,
polyethylene glycol.
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(4 hours: 57.28±4.24%ID/g; 24 hours: 52.95±2.68%ID/g).
Similarly, the intermediate liver uptake of spherical NP4
(4 hours: 34.17±14.35%ID/g; 24 hours: 26.02±4.96%ID/g)
did not significantly change after PEGylation (4 hours:
P=0.6345; 24 hours: P=0.1742). The other nonspherical particle NP1 (4 hours: 39.64±4.56%ID/g; 24 hours:
31.11±5.72%ID/g) and NP3 (4 hours: 63.06±13.29%ID/g;
24 hours: 44.74±4.04%ID/g) revealed higher relative accumulation in that organ. However and in contrast to NP2 and
NP4, PEGylation led to a significant drop in liver uptake of
both NP1 (4 hours: P=0.0003; 24 hours: P,0.0001) and NP3
(4 hours: P=0.0014; 24 hours: P=0.0015).
Overall, the aerosol-synthesized NP2 showed relatively
high uptake into the liver that was time and PEGylation
independent. Similar to this, the intermediate liver uptake
of sol–gel-synthesized NP4 was PEGylation independent.
In contrast, the intermediate (NP1) or high (NP3) liver
uptake of the remaining aerosol-synthesized NPs was clearly
decreased when PEGylated.

Spleen uptake
The analysis of spleen uptakes showed an extremely high
accumulation of non-PEGylated NP3 (nonspherical, low
surface area) after 4 hours (117.97±6.57%ID/g) that was
significantly higher than for all other NPs (all P,0.0003).
This effect of increased spleen uptake of NP3 was mostly
dependent on time and PEGylation status showing lower
submit your manuscript | www.dovepress.com
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uptake after 24 hours (63.01±23.13%ID/g) or PEGylation
(4 hours: 46.71±21.08%ID/g; 24 hours: 27.45±6.66%ID/g).
Calculating the P-values confirmed that the observed differences between non-PEGylated and PEGylated NP3
were significant (4 hours: P,0.0001; 24 hours: P=0.0237).
NP1 revealed intermediate (4 hours: 44.95±12.46%ID/g)
or low (24 hours: 26.66±4.04%ID/g) spleen uptake that
decreased after PEGylation (4 hours: 4.89±1.02%ID/g,
P=0.0106; 24 hours: 4.11±0.58%ID/g, P=0.3267). High
apparent uptake (4 hours: 63.45±24.78%ID/g; 24 hours:
77.02±18.71%ID/g) was seen for the NP2 independent
of PEGylation (4 hours: P=0.9294; 24 hours: P=0.3702).
The spherical control NP4 showed only low spleen uptake
(4 hours: 16.15±7.95%ID/g; 24 hours: 9.13±1.60%ID/g)
also independent of PEGylation (4 hours: P=0.9987;
24 hours: P.0.9999).
In summary, very high initial spleen uptake was
observed for non-PEGylated NP3 that decreased over time.
PEGylation reduced the spleen uptake of NP3 dramatically.
A similar behavior (ie, higher initial spleen uptake when
non-PEGylated) was observed for NP1, although the overall
uptake was clearly lower. In contrast, overall high or low
spleen uptake was observed for NP2 and NP4, respectively,
but independent of time and PEGylation.

Kidney uptake
Uptake of NPs in the kidneys was lower when compared
with the lung, liver, and spleen. Interestingly, the kidney
uptake seemed to be mainly time independent for all
types of NPs. The highest accumulation was seen for the
spherical NP4 (4 hours: 10.59±3.37%ID/g; 24 hours:
12.97±4.78%ID/g), followed by the nonspherical NP3
(4 hours: 8.68±1.32%ID/g; 24 hours: 8.28±0.97%ID/g), NP1
(4 hours: 4.13±0.57%ID/g; 24 hours: 4.08±0.47%ID/g), and
finally NP2 with very low overall kidney uptake (4 hours:
0.62±0.06%ID/g; 24 hours: 0.60±0.07%ID/g). PEGylation
of the nonspherical NPs had no major impact on the kidney
uptake (all P.0.1971). However, PEGylation of the spherical
NP4 was more relevant especially after 24 hours (4 hours:
P=0.0904; 24 hours: P=0.0029), showing an overall reduced
kidney accumulation (4 hours: 7.26±2.09%ID/g; 24 hours:
7.11±0.72%ID/g).
The kidney uptake was higher for the spherical NP4
than for all nonspherical NPs. Almost no differences
between the time points in kidney uptake could be measured. PEGylation had no significant influence on kidney
uptake for the nonspherical NPs and moderate effect on
the spherical NP4 after 24 hours with a slightly decreased
kidney uptake.
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Intestinal uptake
Highest intestinal uptake was observed for nonspherical NP3
(4 hours: 23.96±2.90%ID/g; 24 hours: 17.05±1.97%ID/g),
followed by spherical NP4 (4 hours: 16.92±6.74%ID/g;
24 hours: 13.12±2.02%ID/g), and nonspherical NP1 (4 hours:
12.43±1.21%ID/g; 24 hours: 8.10±1.01%ID/g). As already
seen for the kidneys, the accumulation of NP2 into the intestine was very limited (4 hours: 1.36±0.04%ID/g; 24 hours:
0.82±0.08%ID/g) and significantly lower than for all other
NPs. Independent of the particle morphology, the differences of intestinal uptake to the two different time points
were mostly not significant (all P.0.4076) except for NP3
with a slight significant decrease over time (P=0.0372).
PEGylation did not change intestinal uptake for NP1, NP2,
and NP4 (4 hours: P all .0.7973; 24 hours: P all .0.2321).
However, a significant decrease in intestinal uptake was
observed after PEGylation of NP3 (4 hours: P,0.0001;
24 hours: P=0.0002).
In summary, there was a significantly higher intestinal
uptake of NP3 than for all other NPs, especially to the early
time point. In contrast to all other particles, there was a
significant decrease in the intestinal uptake of NP3 after
PEGylation, especially after 4 hours.

Tumor uptake
Good tumor penetration and retention are essential for the
successful development of NPs as potential vectors for
delivering therapeutic payloads and for imaging cancer.
Figure 4 compares the tumor uptakes for the non-PEGylated
vs PEGylated NPs after 24 hours. In general, the uptake of
NPs into the A431 tumors showed a pattern similar to that
observed for the kidneys. The highest uptake in tumors was
seen for the spherical NP4 (non-PEG: 5.39±1.31%ID/g;
PEG: 5.05±1.30%ID/g), followed by the nonspherical NP3
(non-PEG: 3.61±1.02%ID/g; PEG: 2.70±0.67%ID/g),
NP1 (non-PEG: 1.38±0.10%ID/g; PEG: 0.84±0.33%ID/g),
and NP2 with very low overall tumor uptake (non-PEG:
0.11±0.01%ID/g; PEG: 0.15±0.05%ID/g). By analyzing
the P-values, this pattern was basically independent of time
(NOTA: all P.0.2663; PEG: all P.0.5292) or PEGylation
(4 hours: all P.0.9765; 24 hours: all P.0.7299).
Overall tumor uptake was higher for spherical NP4
than for the nonspherical NPs (NP3.NP1.NP2). In general, tumor uptakes were basically independent of time or
PEGylation.

Tumor-to-organ ratios
Based on the uptakes obtained during the in vivo mice
studies, both tumor-to-blood (TTB) and tumor-to-muscle
International Journal of Nanomedicine 2018:13
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(TTM) ratios were calculated (Table S6), showing nonsignificant differences between both time points (all
P.0.0883). Figure 5A highlights the calculated TTB and
Figure 5B the TTM ratios after 24 hours. Analogous to the
absolute tumor uptakes, the highest ratios were observed
for the spherical NP4 (TTB: 3.13±0.62; TTM: 7.76±0.31)
that was significantly higher than for all the nonspherical
NPs. No significant differences were seen between various
nonspherical NPs neither in TTB (NP1: 1.66±0.31, NP2:
1.38±0.19, and NP3: 1.58±0.50) nor in TTM ratios (NP1:
4.12±1.14, NP2: 4.39±1.36, and NP3: 4.34±1.12). By analyzing the P-values, PEGylation of NPs had no significant
influence on neither the TTB ratio (all P.0.5984) nor the
TTM ratio (all P.0.9891).
In summary, sol–gel-produced NP4 showed higher TTB
and TTM ratios than the aerosol-synthesized NPs. In fact,
no significant difference in ratios of TTB and TTM could
be measured between the aerosol-synthesized NPs. Both
TTB and TTM ratios were independent of the time point and
PEGylation for all investigated NPs.

Discussion
Particle synthesis
In this study, we implemented an aerosol reactor approach to
synthesize morphologically different siliceous NPs of similar
aggregate sizes (~170 nm) for their evaluation in biomedical

A

applications. Based on the process, these compounds are
composed of primary spherical subunits of different sizes (ie,
6, 14, and 41 nm) but form stable aggregates due to thermalinduced sintering during particle synthesis. Most current
technologies for the production of biomedical siliceous NPs
often rely on liquid phase techniques (ie, sol–gel methods
for the synthesis of SiO2NPs)27,39 or top-down approaches
(ie, etching and milling for the fabrication of pSi).19,40 In
contrast, the de novo growing in the gas phase is mainly used
to synthesize smaller (,10 nm) colloidal SiNPs for imaging
applications (eg, Si QDs).33 Here, different technologies
have been established including supersaturated Si vapor
in a microplasma reactor41 or by the pyrolysis of silane gas
in a microwave plasma reactor.42 Last but not least, fumed
silica may be synthesized by high temperature hydrolysis of
SiCl4 in an O2(N2)/H2 flame, where small primary SiO2NPs
(5–50 nm) form branched hard-agglomerates but usually
grow up to micrometer size (0.1–100 µm) and are mainly
used in industrial applications.43 In our approach, we used a
furnace aerosol reactor for the pyrolysis (ie, thermal anoxic
decomposition) of monosilane (SiH4) gas to grow SiNPs of
defined nanometer size and morphologies, which might also
be valuable for biomedical applications. Historically, early
attempts in the aerosol-assisted production of NPs were often
developed empirically since a theoretical understanding of
the physico-chemical details was missing. Indeed, aerosol
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Figure 5 Tumor-to-organ ratios of radiolabeled NPs in tumor-xenografted mice.
Notes: Tumor-to-blood (A) or tumor-to-muscle (B) ratios were calculated based on the biodistribution data for non-PEGylated (left) and PEGylated (right) NP-NOTA64
Cu after 24 hours of circulation. Ratios were calculated separately for each mouse based on the %ID/g data and expressed as mean ± SD involving n=4 mice per group.
Statistical analysis was performed by one-way ANOVA, followed by Tukey’s multiple comparison test (****P,0.0001; ***P,0.001; **P,0.01). Green: NP1, blue: NP2, red:
NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PEG, polyethylene glycol.
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synthesis of SiNPs is composed of several overlapping steps
(chemical reaction, nucleation, growth, agglomeration, and
under some circumstances, sintering) that are challenging
to study due to the high temperatures, short reaction times,
and limited access to track the reaction.44 Nevertheless,
recent improvements in multiscale modeling of the aerosol
synthesis process for SiNPs have allowed better predictions in the synthesis of narrow sized primary particles and
controlling the synthesis process.44 In accordance, we have
developed a reactor setup and process control that allowed
us to produce narrow size distributions of primary SiNPs that
differed depending on the reactor temperature. Yet, the final
size distributions of sintered aggregates remained practically
unaffected during synthesis within a broad temperature range
of 600 to 1,100°C. Based on this observation, we developed
a stable process to synthesize aggregates of similar size distributions but made of primary particles of different sizes to
analyze their potential in biomedical applications.

Particle functionalization
Several approaches are now available to study the biodistribution of NPs, including inductively coupled plasma-optical
emission spectroscopy/mass spectrometry, fluorescence, and
radiolabeling. Based on our long-standing expertise, we performed radiolabeling with 64Cu to evaluate the potential of our
aerosol-synthesized NPs for bio-applications. This technique
requires the covalent linkage of copper chelators (eg, NOTA)
to the particle surface. In general, surface modification of
the SiNPs (eg, colloid Si QDs) can be achieved by various
techniques to generate either hydride or halogen-terminated
surfaces. In a next ligand exchange step, hydrosilylation of
the hydride-terminated or nucleophilic substitution of the
halogen-terminated surfaces is performed to establish robust
covalent linkages between the Si surface atoms and carbon,
nitrogen, or oxygen species.32 These techniques allow the
formation of self-assembled monolayers (SAMs) of a variety
of distal moieties and are highly useful for subsequent functionalization steps. In contrast to these mentioned approaches,
we decided on another widely used strategy of Si surface
modification by adding stable silica shells to the Si cores.
Here, thermal oxidation is by far the most used process due to
its simplicity, adaptability, and relatively low cost of implementation. Thermal oxidation of our aerosol-synthesized Si
particles was performed under morphology-dependent conditions and required high temperatures with varying exposure
times of up to several hours. In general, successful oxidation
of SiNPs can be performed in a wide range of process temperatures (RT to 1,100°C) that requires very little oxygen.45
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Thermal oxidation of SiNPs occurs in a two-step shrinking
core model46 and might result in stable silica layers of different
oxygen contents and sometimes different surface hydride species depending on the condition used for thermal treatment.38
Since all our particles have been processed at a temperature
of $500°C, it can be anticipated that these particles contain
a crystalline Si core, covered by a layer of amorphous Si and
an outer Si oxide shell highly valuable for further particle
functionalization. Moreover, we preferred the silica conversion strategy for the following two additional reasons: first,
SiO2NPs possess prolonged circulation times and in vivo
stabilities compared to their Si counterparts (half-life of days
compared to hours). Second, there are a variety of well-known
silica surface modification technologies on hand including
those based on various commercially available alkoxysilanes
and halosilanes.47 In the case of alkoxysilanes, stable 1–3
Si-O-Si links with the surface silanol groups (≡Si-OH) are
formed in a condensation reaction. Most frequently, APTES
or (3-mercaptopropyl)-trimethoxysilane (MPTMS) is used for
silica surface modification to add either aminopropyl silane
(APS) or mercaptopropyl silane (MPS) films. The covalently
linked primary amines (-NH2) or thiol groups (-SH) of such
modified silica surfaces facilitate the linker chemistry with
other frequently used linking moieties including those based
on n-hydroxysuccinimide (NHS), isothiocyanates (both for
amine coupling), or maleimides (for thiol coupling). In the
current study, the silica surface of our NPs was modified
with primary amines by APTES treatment to allow subsequent functionalization with NHS-functionalized NOTA or
NHS-functionalized PEG. However, APTES treatment has
increased the apparent sizes of our aerosol-synthesized NPs
by about threefold. Since this effect was also observed for
our spherical control particles, we conclude that the particle
aggregation after amine modification was independent of the
morphology. The phenomena of aggregation of SiO2NPs after
APTES treatment can be explained by an excess of positively
charged amino groups on the silica surface at physiological
pH.48 Indeed, APTES treatment of our NPs increased the
ZPs by an average of 44.1±2.8 mV to the low positive range
indicating decreased overall particle stabilities. APTESmodified SiO2NPs are known to back-bond primary amines to
surface silanol groups that might induce particle aggregation
due to the reduced shear plane and electrostatic repulsion.
Subsequent functionalization by NOTA or NOTA/PEG
moieties slightly decreased ZPs but still stayed in the range
of low overall stability (ie, around ±0 mV). Thus, decreasing
the ratio of surface amines to silanol groups should reduce
particle aggregation and improve biocompatibility. Although

International Journal of Nanomedicine 2018:13

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 128.252.174.220 on 29-Dec-2018
For personal use only.

Dovepress

not performed here, quantitative methods to determine the
number of functional amine groups were reported49 and could
help to optimize the condition for surface modification and
to further increase the particle dispersibility. Alternatively,
adding other inert functional groups and/or negatively
charged moieties (eg, methylphosphonate) can increase the
overall solubility by preventing back-bonding48 and might
be a valuable strategy to improve the biocompatibility of our
aerosol-synthesized NPs.

Biodistribution
Silica offers several advantages for biomedical research
compared to other nanomaterials but often suffer from poor
biodistribution with high uptake by the cells of the reticuloendothelial system (RES).20 In terms of passive targeting of solid
tumors, best hydrodynamic stability in the bloodstream of
SiO2NPs is achieved by keeping the particle size between 50
and 300 nm, since particles above 300 nm usually tend to get
recognized by the RES whereas smaller particles (,50 nm)
might nonspecifically distribute in the body.50 More recent
preclinical data suggest that the highest EPR effect in target
tissue can be obtained for NPs with rigid core size between
100 and 220 nm while emphasizing the importance of the
particle surface charge on biodistribution.51 In this regard,
high negative ZPs might improve both stabilities and the EPR
effect, whereas high positive ZPs increase either cytotoxicity (smaller NPs) or recognition by the RES (NPs .150 nm
core size). Based on this knowledge, we implemented the
aerosol reactor technology to generate siliceous NPs with a
final rigid core size of on average ~170 nm and high negative ZP (about -30 mV) to increase the EPR effect in our
tumor model. However, the DLS data suggest that surface
modification (ie, APTES, NOTA, and PEG) increased the
hydrodynamic sizes independent of the particle morphology (.300 nm) that might have reduced tumor penetration
and facilitated RES recognition. The mouse biodistribution studies revealed that the majority of our radiolabeled
SiO2NPs (up to 126%ID/g) accumulated in the organs of the
RES (ie, liver, spleen, and lung), followed by intermediate
uptake (up to 24%ID/g) in the intestine and kidney (Figures 2
and 3). In contrast, the particle accumulation in the other
organs (Tables S2–S5) including blood, muscle, and human
A431 xenografts (Figure 4) was rather low (,6%ID/g).
Despite this general pattern of organ distribution, the relative organ uptakes of the SiO2NPs varied dependently on the
particle morphology. For instance, aerosol-synthesized NP1
composed of small primary particles highly accumulated in
lungs at the early time point (109%ID/g) but dramatically
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decreased after only 24 hours (lung uptake NP1: ,13%ID/g),
an effect that was much stronger than for any of the other
investigated NPs. Initially increased lung concentrations
of SiO2NPs that decreased over time have been described
previously and were suggested to be caused by the uptake
and migration of alveolar phagocytes.52 We conclude that the
unique morphology with high surface area of NP1 increased
the uptake by alveolar phagocytes, although an initial blockage of small lung capillaries by NP1 might have contributed
to this effect as well. Similarly, the unique morphology of
aerosol-synthesized NP3 resulted in strong initial spleen
uptake (4 hours: 118%ID/g vs 24 hours: 63%ID/g) that
was likely caused by the preferred uptake of NP3 through
spleen macrophages. Nevertheless, our 24 hour biodistribution data suggest that the majority of injected particles accumulated in the liver independent of the particle morphology.
Being the largest organ of the mouse body (around 1 g),
calculation of the organ uptake (%ID/organ) indeed revealed
high liver accumulation for all particles (NP1: 34%, NP2:
61%, NP3 48%, and NP4: 25%). This is in accordance with
other reports indicating that the liver usually sequesters the
majority (up to 99%) of administered NPs from the bloodstream and typically less than 5% of the injected NPs are
delivered to the diseased tissue.53 As a matter of fact, tumor
uptakes were highly dependent on the particle morphology.
Here, aerosol-synthesized NPs with large primary subunits
and smaller overall surface area (NP3) showed superior
tumor penetration and retention compared to those made of
smaller primary subunits (ie, NP1 and NP2). Interestingly,
PEGylation of our aerosol-synthesized NPs showed minor
effects on blood circulation and uptake by tumors. This is
in contrast to many studies, although there are some studies
that have demonstrated that PEGylation can have a minimal
effect on tumor uptake.54,55 Nevertheless, we did observe
some differences between PEGylated and non-PEGylated
NPs in organs of the RES (eg, reduced liver and spleen
uptake by NP1 and NP3). The DLS data suggest that PEGylation might have impaired efficient tumor penetration of the
aerosol-synthesized NPs due to an increase in hydrodynamic
radius above the critical cutoff size for efficient microvascular
permeability (ie, 400–600 nm for most tumors).56 In fact,
our aerosol-synthesized NPs, in general, showed a higher
susceptibility for aggregation after PEGylation than the
spherical NP4 possessing the highest tumor uptake, TTB, and
TTM ratios of all particles. In general, nonspecific uptake
of SiO2NPs through the RES does not lead to any long-term
toxicity since decomposition and clearance of SiO2NPs,
though biliary (ie, feces) and renal system (ie, urine) usually
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occurs within a few weeks.22 We believe that our SiO2NPs
would have a similar low toxicity; however, this will need
to be confirmed in future studies. Nevertheless, drug-loaded
therapeutic NPs might result in systemic toxicity if nonspecifically unloaded in nontarget tissue. In this regard, further
fine-tuning of our functionalization procedure is warranted
to reduce the particle aggregation and RES uptake.

Conclusion
The goal of this study was to evaluate the general biodistribution of siliceous NPs that were synthesized by a novel
aerosol reactor-based approach and to further demonstrate
the feasibility of this technology to generate biodegradable
NPs with biomedical potential. In vivo biodistribution of
the 64Cu-radiolabeled NPs revealed predominant uptake by
the phagocytic cells of the RES in liver (Kupffer cells), spleen
(red pulp macrophages), and lung (alveolar macrophages).
The significant differences of the aerosol-synthesized NPs in
organ distribution were mainly caused by the different morphologies of the investigated particles, although the change
of other physiochemical characteristics (eg, hydrodynamic
size and ZP) might have contributed to this effect as well.
In terms of the highest tumor uptake and retention, aerosolsynthesized NPs composed of large primary subunits and
smaller overall surface area (NP3) seemed to be superior
over those composed of smaller subunits (NP1 and NP2),
suggesting the potential of NP3 in the development as a tumor
imaging or therapeutic agent. Although similar technologies
for the synthesis of siliceous particles by aerosol reactors
have been reported previously, this study represents, to our
knowledge, the first investigation regarding the potential of
such synthesized NPs for biomedical applications. Nevertheless, we observed a high uptake of our NPs by the RES
that is in accordance with many other in vivo reports about
siliceous NPs for biomedicine. In this regard, further optimization of the synthesis and functionalization process of our
aerosol-derived NPs seems to be warranted to improve tumor
penetration and retention in upcoming studies. In terms of
synthesis, adjusting the reactor conditions to produce larger
primary subunits of sintered or even spherical nonsintered
particles might be favorable. Last but not least, incorporation
of functional groups (eg, organosilica) during the aerosol
synthesis process to produce organosilica or silsesquioxane
NPs might further expand the potential of this technology
in terms of biomedical usage. Overall, the current data
suggest that the silane aerosol reactor approach is valuable
in generating sintered siliceous aggregates on a nanoscale
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that are safe and promising for use in future imaging and/or
therapeutic applications.
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Figure S1 Silane aerosol reactor for the production of siliceous NPs.
Notes: (A) The setup of the aerosol reactor allowing the controlled synthesis of nonspherical SiNPs by the pyrolysis of silane gas in a Lindberg furnace. The rector
temperature had a major impact on the primary particle size of formed SiNPs (B). The smallest primary particles were seen at 600°C steadily growing in size up to about
900°C. Above this temperature, primary particle sizes only slightly decreased but formed highly spherical primary particle shapes. Reactor conditions were chosen to produce
three types of NPs (NP1, NP2, and NP3) with similar final aggregate size distribution as live-monitored by a SMPS (C). SiNPs were finally converted into SiO2 by thermal
oxidation as obvious by change in color from gray/black to white (D).
Abbreviations: NP, nanoparticle; SMPS, scanning mobility particle sizer.

Table S1 Reactor conditions and parameters
Sample

Reactor
temperature (°C)

Silane
concentration (%)

Reactor operation
time (hours)

Residence
time (s)

Relative primary
particle size

NP1
NP2
NP3

1,000
600
1,000

0.004
0.02
0.02

10
10
10

0.28±0.03
2.14±0.13
1.47±0.09

Small
Intermediate
Large

Notes: Green: NP1, blue: NP2, red: NP3.
Abbreviation: NP, nanoparticle.
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Figure S2 Primary particle sizes of NPs by TEM analysis.
Notes: Primary subunits of the aerosol reactor produced nonspherical NP1 (A), NP2 (B), NP3 (C), and the sol–gel-produced spherical NP4 (D) were analyzed by ImageJ
employing TEM pictures of the final products. In case of the nonspherical NPs, frequency distributions are based on area measurements of randomly chosen primary subunits
assuming spherical subunits for calculating particle diameters. In case of NP4, the areas of the single monodisperse spheres were measured to confirm the final particle sizes.
Histograms were created by GraphPad Prism implicating a Gaussian distribution. Sizes were calculated as mean ± SD based on 100 independent measurements.
Abbreviations: NP, nanoparticle; TEM, transmission electron microscope.

Table S2 Biodistribution of NP-NOTA-64Cu in A431 tumor-xenografted mice after 4 hours
Organ
Tumor
Blood
Muscle
Lung
Liver
Spleen
Kidney
Bladder
Heart
Bone
Pancreas
Stomach
Intestine

NP1-NOTA-64Cu

NP2-NOTA-64Cu

NP3-NOTA-64Cu

NP4-NOTA-64Cu

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

1.37
1.06
0.33
108.84
39.64
44.95
4.13
0.79
2.06
0.95
0.97
1.43
12.43

0.53
0.09
0.04
19.07
4.56
12.46
0.57
0.13
0.21
0.21
0.13
0.49
1.21

0.08
0.10
0.04
5.19
57.28
63.45
0.62
0.11
0.21
0.46
0.14
0.44
1.36

0.02
0.02
0.02
1.67
4.24
24.78
0.06
0.05
0.04
0.11
0.05
0.16
0.04

3.26
2.07
0.67
25.75
63.06
117.97
8.68
1.96
2.81
2.12
1.86
2.63
23.96

0.94
0.41
0.05
3.27
13.29
6.57
1.32
0.26
0.44
0.31
0.36
0.32
2.90

3.37
1.74
0.52
37.46
34.17
16.15
10.59
1.07
2.08
1.28
1.30
1.70
16.92

2.64
0.69
0.19
5.92
14.35
7.95
3.37
0.44
0.86
0.50
0.53
0.82
6.74

Notes: Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.
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Table S3 Biodistribution of NP-NOTA-64Cu in A431 tumor-xenografted mice after 24 hours
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Organ
Tumor
Blood
Muscle
Lung
Liver
Spleen
Kidney
Bladder
Heart
Bone
Pancreas
Stomach
Intestine

NP1-NOTA-64Cu

NP2-NOTA-64Cu

NP3-NOTA-64Cu

NP4-NOTA-64Cu

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

1.38
0.85
0.35
12.86
31.11
26.66
4.08
0.89
1.94
0.98
0.97
1.57
8.10

0.10
0.12
0.08
3.37
5.72
4.04
0.47
0.23
0.33
0.09
0.22
0.31
1.01

0.11
0.08
0.03
1.28
52.95
77.02
0.60
0.12
0.18
0.48
0.13
0.46
0.82

0.01
0.02
0.09
0.15
2.68
18.71
0.07
0.06
0.04
0.10
0.02
0.32
0.08

3.61
2.32
0.83
16.12
44.74
63.01
8.28
1.85
3.73
2.52
1.91
2.07
17.05

1.02
0.29
0.08
4.83
4.04
23.13
0.97
0.38
0.40
0.73
0.36
0.35
1.97

5.39
1.73
0.69
14.28
26.02
9.13
12.97
1.72
3.05
2.00
1.64
2.32
13.12

1.31
0.31
0.15
6.59
4.96
1.60
4.78
1.05
0.59
0.45
0.23
0.72
2.02

Notes: Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle.

Table S4 Biodistribution of PEGylated NP-NOTA-64Cu in A431 tumor-xenografted mice after 4 hours
Organ
Tumor
Blood
Muscle
Lung
Liver
Spleen
Kidney
Bladder
Heart
Bone
Pancreas
Stomach
Intestine

NP1-NOTA-PEG-64Cu

NP2-NOTA-PEG-64Cu

NP3-NOTA-PEG-64Cu

NP4-NOTA-PEG-64Cu

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

0.84
0.64
0.29
126.06
8.99
4.89
2.93
0.69
1.41
0.53
0.75
1.12
9.53

0.27
0.09
0.08
14.51
0.91
1.02
0.31
0.11
0.08
0.13
0.07
0.20
1.14

0.18
0.20
0.07
25.41
64.54
75.30
1.93
0.28
0.73
0.93
0.30
1.43
2.86

0.03
0.04
0.01
5.91
4.07
16.73
0.07
0.15
0.06
0.31
0.15
0.60
0.50

2.72
1.49
0.45
34.74
36.34
46.71
5.80
1.22
2.10
1.79
1.22
1.84
5.77

0.51
0.21
0.09
8.67
5.53
21.08
1.20
0.12
0.35
0.34
0.33
0.46
1.01

4.11
1.33
0.46
36.54
24.28
10.21
7.26
1.02
2.04
1.18
1.31
1.86
16.60

1.06
0.06
0.04
5.93
4.63
2.89
2.09
0.12
0.20
0.18
0.22
0.38
1.21

Notes: Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PEG, Polyethylene
glycol.

Table S5 Biodistribution of PEGylated NP-NOTA-64Cu in A431 tumor-xenografted mice after 24 hours
Organ
Tumor
Blood
Muscle
Lung
Liver
Spleen
Kidney
Bladder
Heart
Bone
Pancreas
Stomach
Intestine

NP1-NOTA-PEG-64Cu

NP2-NOTA-PEG-64Cu

NP3-NOTA-PEG-64Cu

NP4-NOTA-PEG-64Cu

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

%ID/g

± SD

0.84
0.56
0.24
20.23
6.85
4.11
2.53
0.44
1.19
0.57
0.64
0.90
5.36

0.33
0.27
0.10
5.72
2.18
0.58
0.88
0.18
0.37
0.18
0.24
0.28
1.64

0.15
0.11
0.04
2.11
55.77
55.29
1.11
0.12
0.25
1.03
0.15
0.30
1.33

0.05
0.03
0.01
0.38
8.33
23.86
0.17
0.07
0.05
0.18
0.03
0.14
0.03

2.70
1.34
0.54
16.59
26.63
27.45
5.29
1.01
2.53
1.77
1.26
1.24
10.86

0.67
0.33
0.12
6.92
8.30
6.66
1.14
0.31
0.70
0.48
0.32
0.47
2.36

5.05
1.35
0.62
14.89
15.88
6.01
7.11
1.08
2.77
1.52
1.57
2.16
11.06

1.30
0.08
0.06
5.78
1.88
1.50
0.72
0.33
0.38
0.30
0.11
0.43
1.24

Notes: Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; %ID/g, percentage of injected dose per gram; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacyclononane; NP, nanoparticle; PEG, polyethylene
glycol.
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Table S6 Tumor-to-organ ratios of radiolabeled NPs in tumorxenografted mice
Sample

TTB
ratio ± SD

TTM
ratio ± SD

NP1-NOTA-64Cu: 4 hours
NP1-NOTA-PEG-64Cu: 4 hours
NP1-NOTA-64Cu: 24 hours
NP1-NOTA-PEG-64Cu: 24 hours

1.28±0.43
1.31±0.34
1.66±0.31
1.56±0.25

4.12±1.37
2.95±0.49
4.12±1.14
3.55±0.47

NP2-NOTA-64Cu: 4 hours
NP2-NOTA-PEG-64Cu: 4 hours
NP2-NOTA-64Cu: 24 hours

0.80±0.18
0.92±0.21
1.38±0.19

2.41±0.67
2.53±0.21
4.39±1.36

NP2-NOTA-PEG-64Cu: 24 hours
NP3-NOTA-64Cu: 4 hours
NP3-NOTA-PEG-64Cu: 4 hours
NP3-NOTA-64Cu: 24 hours
NP3-NOTA-PEG-64Cu: 24 hours
NP4-NOTA-64Cu: 4 hours
NP4-NOTA-PEG-64Cu: 4 hours
NP4-NOTA-64Cu: 24 hours
NP4-NOTA-PEG-64Cu: 24 hours

1.35±0.14
1.57±0.30
1.85±0.46
1.58±0.50
2.04±0.32
1.95±1.14
3.08±0.76
3.13±0.62
3.77±1.02

4.32±1.41
5.35±0.74
6.17±0.87
4.34±1.12
4.98±0.75
6.60±4.19
9.03±2.79
7.76±0.31
8.12±1.40

Notes: Green: NP1, blue: NP2, red: NP3, orange: NP4.
Abbreviations: 64Cu, copper-64; NOTA, 1,4,7-tricarboxymethyl-1,4,7-triazacy
clononane; NP, nanoparticle; PEG, polyethylene glycol; TTB, tumor-to-blood; TTM,
tumor-to-muscle.
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